Adipo Therapeutics

Transforming fat, changing lives.

About Us

Imagine being able to transform energy-storing white fat into energy-burning brown fat. That’s the concept behind a first-in-class therapy that could soon treat obesity and type 2 diabetes. Adipo Therapeutics, an Indiana biotechnology company, is developing polymer-based, Notch-inhibiting nanoparticles that are injected directly into adipose (fat) tissue to induce browning, or white-to-beige adipocyte transformation. The goal? Reducing weight and restoring metabolic balance for millions of people living with diabetes.

Our Vision

Our vision is to transform the treatment of obesity and type 2 diabetes. While current treatments focus on increasing exercise, decreasing food intake, and increasing insulin, Adipo believes there is another option. Transformation of adipose tissue through browning has the potential to use the body’s own physiology to raise energy expenditure, reduce adiposity, and improve insulin resistance.

Our Approach

Adipo Therapeutics is developing an innovative technology platform of localized, polymer-based nanoparticulate delivery of Notch inhibitors to induce adipocyte browning in specific white fat depots. Once enough adipocyte transformation has occurred, the physiological effects resulting from local browning of adipose tissue will become systemic and drive greater energy expenditure and improved insulin sensitivity. Adipo’s innovative therapy combines the recent discovery of the role played by Notch signaling in adipocyte browning, with advances in polymer-based drug delivery to minimize the risk of systemic toxicity. Adipo’s treatment offers the potential of a unique value proposition for the treatment of type 2 diabetes, providing sustainable weight loss, improved glucose homeostasis and systemic metabolism, with minimized off-target side effects.

Watch the video

Adipo's treatment offers the potential of a unique treatment for type 2 diabetes. Localized drug delivery that transforms the body's own fat to burn energy and improve insulin resistance, resulting in sustained weight loss and blood glucose control.

Our Team

+

Meng Deng, PhD.

Founder & President

Meng Deng, PhD.

Founder & President

About Meng

Meng Deng, PhD. is the Founder and President of Adipo Therapeutics. The breakthrough technology of Adipo Therapeutics stems from his strong commitment and 15+ years of experiences on development of biomaterials-based translational technologies for cell engineering, tissue engineering, and drug delivery. Dr Deng is an Assistant Professor of Biological Engineering, Biomedical Engineering, and Materials Engineering at Purdue University. Dr. Deng received a B.E. in Chemical Engineering in 2004 from Tsinghua University, China, a Ph.D. in Chemical Engineering from the University of Virginia in 2010, and postdoctoral research at the University of Connecticut Health Center and MIT. He was the recipient of Young Scientist Award from the 9th World Biomaterials Congress. Dr. Deng has more than 50 publications, one edited book, and 10+ patents/disclosures in the fields of biomaterials, drug delivery, nanotechnology, and regenerative engineering

+

Karen Wurster, MBA

CEO

Karen Wurster, MBA

CEO

About Karen

Karen Wurster, MBA is the CEO of Adipo Therapeutic. Ms. Wurster has over 25 years of leadership experience in the pharmaceutical industry, where she dedicated her career to the development and launch of treatments for diabetes, launching more than 10 diabetes products and leading in areas including New Product Planning, Life Cycle Management, Global Brand Management, and US Commercialization. Karen is a proven transformative leader with demonstrated strength in recruiting, developing, and engaging teams to deliver strong results on a shared vision of success.Karen most recently worked as a strategic pharmaceutical marketing consultant, providing her expertise to companies developing and launching new products in diabetes and obesity. Her responsibilities at Adipo focus on developing a clear path to commercialization for the technology and cultivating potential collaborators and acquisition partners. Karen has a BS in biochemistry from Indiana University, and an MBA in finance from the IU Kelley School of Business.

+

Roger Miller, MBA, MS

Vice President of Operations

Roger Miller, MBA, MS

Vice President of Operations

About Roger

Roger Miller, MBA, MS serves as the Vice President of Operations for Adipo. He brings multiple years of experience in the pharmaceutical industry and biotech start-ups including leadership roles in R&D, Manufacturing, Quality and Human Resources, and Corporate Business Development. His experience has been built in leadership roles at Eli Lilly, AcquiRight, Targanta, BioCritica, Iterion Therapeutics, Salarius Pharmaceuticals, and Apexian Pharma (Apex Therapeutics). Roger’s educational background includes two graduate degrees from Purdue University MBA in Operations and MS in Physical Chemistry. He earned his BA in Chemistry from Indiana University at Indianapolis.

Our Investors & Partners

Contact Us